26 to 27 July 2024
The Science Of
HBV Cure
Meeting 2024
8:30 am to 5:00 pm (SGT)
The Science Of Hbv Cure Meeting 2024
The format (Live or Online) of the Science of HBV Cure Meeting 2024 will be confirmed by the end of March 2024.
MEET SOME OF OUR EXPERTS
Prof. Lim Seng Gee
The Science of HBV Cure Meeting 2024 Preliminary Draft Scientific Programme.
July, 2024
26
| Programme | Time (SGT) |
|---|---|
| Welcome Remarks by the Conference Chairman | 10:00 – 10:10 |
| Opening Symposium: Overview of HBV Functional Cure Moderators: |
|
| Drug development in CHB: prospects for functional cure | 10:10 – 10:30 |
| ICE-HBV developments 2024 | 10:30 – 10:45 |
| HBV Forum update | 10:45 – 11:00 |
| Virologal Insights into functional cure Moderators: |
|
| Which virological targets can lead to functional cure? | 11:00 – 11:20 |
| Strategies to silence cccDNA | 11:20 – 11:40 |
| Removing integrated HBV | 11:40– 12:00 |
| Free Paper: | 12:00 – 12:15 |
| Free paper: | 12:15 – 12:30 |
| Lunch | 12:40 – 13:20 |
| Immunological insights into functional cure Chairs and Moderator: |
|
| What we have learnt from interrogating the liver microenvironment | 13:30– 13:50 |
| Novel therapeutics in HIV for HBV functional cure | 13:50– 14:10 |
| Free Paper Presentations | |
| Free paper: | 14:10 – 14:25 |
| Strategies to reduce viral replication Chairs and Moderator: |
|
| Prospects for capsid inhibitors to achieve functional cure? | 14:25 – 14:45 |
| Invited Oral & Free Paper Presentations | |
| Assembly Biosciences | 15:45 – 16:00 |
| Free paper: | 16:00 – 16:15 |
| Ascletis | 16:15 – 16:30 |
| Tea Break | 16:30–16:45 |
| Viewpoint Chairs and Moderator: |
|
| Gene editing for functional cure debate Achievable: Too challenging: |
16:45 – 17:15 |
| Invited Oral & Free Paper Presentations | |
| Invited presentation: Abbott Diagnostics |
17:15 – 17:30 |
| Free paper: | 17:30 – 17:45 |
| Closing remarks | 17:45 – 17:50 |
| End of day 1 | |
July, 2024
27
| Programme | Time (SGT) |
|---|---|
| Reducing viral antigens Chair and Moderators: |
|
| Special Lecture: Making sense of anti-sense & siRNA | 09:30 – 09:50 |
| Tea Break | 10:30 – 10:45 |
| Invited Oral & Free Paper Presentations
Chair and Moderators: |
|
| Invited presentation: Roche Assets in HBV Roche |
10:45 – 11:00 |
| Invited presentation: GSK |
11:00 – 11:15 |
| Invited presentation: VIR Bio |
11:15 – 11:30 |
| Invited presentation: Arbutus Biopharma |
11:30 – 11:45 |
| Delta Cure Chairs and Moderator: |
|
| The role of NAPs in Delta Therapy | 12:05 – 12:20 |
| Novel therapeutics in HIV for HBV functional cure Replicor |
12:05 – 12:20 |
| Lunch | 12:20 – 13:00 |
| Immunology Forum Chairs and Moderator: |
|
| Understanding the immune mechanisms for functional cure | 13:35 – 13:55 |
| Therapeutic vaccines for functional cure debate Highly promising: Not promising: |
13:55 – 14:15 |
| Invited Oral & Free Paper Presentations | |
| Gilead HBV Cure Strategy & Portfolio Gilead Sciences |
14:35 – 14:50 |
| Free paper: | 15:05– 15:20 |
| Combination Therapy Forum 1 Chairs and Moderator: |
|
| Immunotherapy and antiviral therapy forum | 15:20 – 16:05 |
| Tea Break | 16:05 – 16:20 |
| 16:20–17:05 | |
| Closing remarks from Chairman | 17:05 – 17:10 |